Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/14/2024 | $5.00 | Buy | Rodman & Renshaw |
| 1/18/2022 | $5.00 → $3.00 | Buy | HC Wainwright & Co. |
| 9/7/2021 | $5.50 → $5.00 | Buy | HC Wainwright & Co. |
8-K - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
424B5 - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
10-Q - ROCKWELL MEDICAL, INC. (0001041024) (Filer)
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Rockwell Medical (NASDAQ:RMTI) with a Buy and maintains $9 price target.
Rockwell Medical (NASDAQ:RMTI) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is a 80 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $22.68 million which beat the analyst consensus estimate of $21.70 million by 4.50 percent. This is a 15.29 percent increase over sales of $19.67 million the same period last year.
Universal Display Corporation (NASDAQ:OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, today announced that Dr. Nigel Brown and Dr. Joan Lau have joined the Company's Board of Directors, effective March 4, 2024. The addition of these new directors expands UDC's Board to ten members. "I am pleased to welcome Nigel and Joan to the Board," said Steven V. Abramson, President and Chief Executive Officer of Universal Display Corporation and a member of the Board. "Nigel adds a wealth of business innovation, technical knowledge and corporate strategic planning expertise to our Board. Joan brings over two decades of extensive scienti
Brings more than 20 years of experience as an entrepreneur scientist, CEO, operator, investor, and board member of public and private biopharmaceutical companies Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company appointed Joan Lau, Ph.D. to its board of directors. Dr. Lau's appointment increases Rockwell Medical's board of directors to seven members. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231017906241/en/RMTI) (Photo: Business Wire)"
WIXOM, Mich. , June 22, 2022 /PRNewswire/ -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that the Board of Directors has appointed Mark Strobeck, Ph.D., as President and Chief Executive Officer, effective July 1, 2022. Dr. Strobeck will also join the Company's Board of Directors. Russell Ellison, M.D., M.Sc., will be stepping down as President and Chief Executive Officer and as a member of the Company's Board of Directors effective June 30, 2022. "We are exci
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that the Company entered into a distribution agreement with Nephro Group Dialysis Centers ("Nephro Group"), the largest dialysis provider in the Philippines. Under the terms of the agreement, Rockwell Medical will be the exclusive supplier of all dry hemodialysis concentrates products, including its CitraPure® Acid and RenalPure® Bicarbonate, to Nephro Group. "Nephro Group was founded in 1995 with the vision to provide all Filipinos high quality, accessible, and affordab
Reports net product sales of $28.3 million for the third quarter of 2024, an increase of 31% over net product sales for the same period in 2023. Net product sales for the third quarter of 2024 included a special large order of premium-priced products by our largest customer. Reports gross profit of $6.2 million for the third quarter of 2024, an increase of 183% over the same period in 2023. Achieves gross margin of 22% for the third quarter of 2024 compared to a gross margin of 9% for the same period in 2023. Generates $4.3 million in cash flow from operations for the third quarter of 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops
Due to the U.S. Securities and Exchange Commission (SEC) and its Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system being closed on Monday, November 11, 2024 in observance of Veteran's Day, the Company will release its financial and operational results for the Third Quarter 2024 on Tuesday, November 12, 2024 Press release will be issued at 6:00am ET followed by a live conference call and webcast at 8:00am ET Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has updated the date for its third quart
Rodman & Renshaw initiated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00
HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $3.00 from $5.00 previously
HC Wainwright & Co. reiterated coverage of Rockwell Medical with a rating of Buy and set a new price target of $5.00 from $5.50 previously
SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13G/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
SC 13D/A - ROCKWELL MEDICAL, INC. (0001041024) (Subject)
Reports net product sales of $28.3 million for the third quarter of 2024, an increase of 31% over net product sales for the same period in 2023. Net product sales for the third quarter of 2024 included a special large order of premium-priced products by our largest customer. Reports gross profit of $6.2 million for the third quarter of 2024, an increase of 183% over the same period in 2023. Achieves gross margin of 22% for the third quarter of 2024 compared to a gross margin of 9% for the same period in 2023. Generates $4.3 million in cash flow from operations for the third quarter of 2024. Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops
Due to the U.S. Securities and Exchange Commission (SEC) and its Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system being closed on Monday, November 11, 2024 in observance of Veteran's Day, the Company will release its financial and operational results for the Third Quarter 2024 on Tuesday, November 12, 2024 Press release will be issued at 6:00am ET followed by a live conference call and webcast at 8:00am ET Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it has updated the date for its third quart
Rockwell Medical, Inc. (the "Company") (NASDAQ:RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced that it will release its financial and operational results for the third quarter ended September 30, 2024 on Monday, November 11, 2024. The Company will issue a press release at 6:00am ET followed by a live conference call and webcast at 8:00am ET. CONFERENCE CALL AND WEBCAST DETAILS Date: Monday, November 11, 2024 Time: 8:00am ET Live Number: (888) 660-6347 // (International) 1 (929) 201-6594 Conference Call ID: 4944610 Webcast and Replay: www.RockwellMed.com/Result
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)
4 - ROCKWELL MEDICAL, INC. (0001041024) (Issuer)